Confluent Surgical Announces Appointment of Frank Ryan to Board of Directors

Apr 10, 2001, 01:00 ET from Confluent Surgical Incorporated

    WALTHAM, Mass., April 10 /PRNewswire/ -- Confluent Surgical Incorporated
 today announced the appointment of Frank J. Ryan to its board of directors.
     Mr. Ryan is a senior executive with over thirty-five years of experience
 in the medical device arena.  Most recently he was the Company Group Chairman
 at Johnson and Johnson, with responsibility for the Worldwide Ethicon
 franchise including Ethicon U.S. and all domestic divisions, Ethicon Europe,
 Worlwide Operations and International Franchise Marketing.  Prior to this he
 was the President of Ethicon, Inc. and also held various executive positions
 in marketing and operations. On behalf of Johnson and Johnson, Mr. Ryan
 coordinated several major acquisitions including Mitek Surgical Products,
 FemRx, Medscand, Innovasive Devices and most recently Heartport.  Additionally
 during his tenure, Ethicon completed several important licensing agreements
 with companies including Closure Medical and Bypass Medical.  Mr. Ryan holds a
 B.S. degree in Mechanical Engineering from the Illinois Institute of
 Technology and an MBA from the University of Chicago, Graduate School of
 Business.
     "I can think of few individuals with a greater understanding of the
 surgical and biomaterials marketplace than Frank, who has been at the helm of
 the world's leading wound care company for several years. We at Confluent feel
 truly privileged to have him join the board" said Amar Sawhney, President and
 CEO of Confluent Surgical, Inc. on Mr. Ryan's appointment.
     "Frank has a demonstrated track record of identifying and growing new
 business opportunities.  We are looking forward to having him help realize the
 full potential of the adhesion prevention opportunity", commented Farhad
 Khosravi, Chairman of Confluent Surgical, Inc. and President and CEO of
 Embolic Protection, Inc., now a Boston Scientific Company.
     Also serving on Confluent's board are William Tidmore, former President of
 DePuy AcroMed, Rodney Altman, M.D. of Techno Venture Management, Daniel Cole
 of Spray Venture Partners and Charles Warden of Schroder Venture Life
 Sciences.
 
     Confluent Surgical, Inc. is a privately held company developing products
 based on its technology platform of in-situ polymerized biomaterials and
 associated delivery systems.  Confluent's lead product, SprayGel(TM), a
 hydrogel for post-surgical adhesion prevention that can be sprayed on in
 laparoscopic as well as open surgery, is currently undergoing multi-center
 clinical evaluation in the U.S. and is expected to be commercialized shortly
 in Europe.
 
     For more information please visit Confluent's web site at
 www.confluentsurgical.com.
 
     CONTACT: Paul Bartlett, (781) 693-2327; email: info@confluentsurgical.com
 
 

SOURCE Confluent Surgical Incorporated
    WALTHAM, Mass., April 10 /PRNewswire/ -- Confluent Surgical Incorporated
 today announced the appointment of Frank J. Ryan to its board of directors.
     Mr. Ryan is a senior executive with over thirty-five years of experience
 in the medical device arena.  Most recently he was the Company Group Chairman
 at Johnson and Johnson, with responsibility for the Worldwide Ethicon
 franchise including Ethicon U.S. and all domestic divisions, Ethicon Europe,
 Worlwide Operations and International Franchise Marketing.  Prior to this he
 was the President of Ethicon, Inc. and also held various executive positions
 in marketing and operations. On behalf of Johnson and Johnson, Mr. Ryan
 coordinated several major acquisitions including Mitek Surgical Products,
 FemRx, Medscand, Innovasive Devices and most recently Heartport.  Additionally
 during his tenure, Ethicon completed several important licensing agreements
 with companies including Closure Medical and Bypass Medical.  Mr. Ryan holds a
 B.S. degree in Mechanical Engineering from the Illinois Institute of
 Technology and an MBA from the University of Chicago, Graduate School of
 Business.
     "I can think of few individuals with a greater understanding of the
 surgical and biomaterials marketplace than Frank, who has been at the helm of
 the world's leading wound care company for several years. We at Confluent feel
 truly privileged to have him join the board" said Amar Sawhney, President and
 CEO of Confluent Surgical, Inc. on Mr. Ryan's appointment.
     "Frank has a demonstrated track record of identifying and growing new
 business opportunities.  We are looking forward to having him help realize the
 full potential of the adhesion prevention opportunity", commented Farhad
 Khosravi, Chairman of Confluent Surgical, Inc. and President and CEO of
 Embolic Protection, Inc., now a Boston Scientific Company.
     Also serving on Confluent's board are William Tidmore, former President of
 DePuy AcroMed, Rodney Altman, M.D. of Techno Venture Management, Daniel Cole
 of Spray Venture Partners and Charles Warden of Schroder Venture Life
 Sciences.
 
     Confluent Surgical, Inc. is a privately held company developing products
 based on its technology platform of in-situ polymerized biomaterials and
 associated delivery systems.  Confluent's lead product, SprayGel(TM), a
 hydrogel for post-surgical adhesion prevention that can be sprayed on in
 laparoscopic as well as open surgery, is currently undergoing multi-center
 clinical evaluation in the U.S. and is expected to be commercialized shortly
 in Europe.
 
     For more information please visit Confluent's web site at
 www.confluentsurgical.com.
 
     CONTACT: Paul Bartlett, (781) 693-2327; email: info@confluentsurgical.com
 
 SOURCE  Confluent Surgical Incorporated